ACORN CAPITAL ADVISORS, LLC — 13F Holdings & Portfolio
CIK 2054410 · latest 13F-HR filed 2026-05-15
ACORN CAPITAL ADVISORS, LLC manages $351.8M in 13F-reported U.S. long-equity assets across 22 reported positions as of its 2026-03-31 13F-HR filing. Its largest disclosed positions are TERN (26.17%), CGON (21.77%), URGN (8.55%). Quarter over quarter (versus its 2025-12-31 filing) the fund opened 2 new positions, exited 1, added to 10, and trimmed 7.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
$351.8M
Long-equity book
22
Distinct positions
2026-03-31
Filed 2026-05-15
+2 / −1 / ↑10 / ↓7
vs 2025-12-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- CG ONCOLOGY INC$29.6M +63.0%
- TERNS PHARMACEUTICALS INC$21.5M +30.5%
- ONKURE THERAPEUTICS INC$3.5M +42.8%
- LEONABIO, INC.$2.7M +71.7%
- CANDEL THERAPEUTICS INC$2.6M +18.0%
Top Trims
- HELUS PHARMA INC.-$5.5M -42.6%
- UROGEN PHARMA LTD-$3.8M -11.3%
- VERASTEM INC-$3.6M -31.3%
- CARDIF ONCOLOGY INC-$2.7M -48.2%
- JASPER THERAPEUTICS-$2.0M -62.0%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | TERNS PHARMACEUTICALS INC | TERN | 880881107 | $92.1M | 26.17% | 1,746,264 | SH |
| 2 | CG ONCOLOGY INC | CGON | 156944100 | $76.6M | 21.77% | 1,130,501 | SH |
| 3 | UROGEN PHARMA LTD | URGN | M96088105 | $30.1M | 8.55% | 1,673,420 | SH |
| 4 | PUMA BIOTECHNOLOGY INC | PBYI | 74587V107 | $26.4M | 7.50% | 4,131,299 | SH |
| 5 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $25.6M | 7.27% | 2,144,844 | SH |
| 6 | CANDEL THERAPEUTICS INC | CADL | 137404109 | $17.2M | 4.89% | 3,497,948 | SH |
| 7 | BICARA THERAPEUTICS | BCAX | 055477103 | $12.8M | 3.64% | 643,382 | SH |
| 8 | ONKURE THERAPEUTICS INC | OKUR | 68277Q105 | $11.8M | 3.34% | 2,839,674 | SH |
| 9 | JADE BIOSCEINCES INC | JBIO | 008064206 | $11.1M | 3.14% | 786,760 | SH |
| 10 | PROTARA THERAPEUTICS INC | TARA | 74365U107 | $9.1M | 2.59% | 1,752,115 | SH |
| 11 | VERASTEM INC | VSTM | 92337C203 | $7.8M | 2.21% | 1,469,153 | SH |
| 12 | HELUS PHARMA INC. | HELP | 23256X407 | $7.4M | 2.10% | 1,540,266 | SH |
| 13 | LEONABIO, INC. | LONA | 04746L203 | $6.5M | 1.85% | 634,539 | SH |
| 14 | AURA BIOSCIENCES INC | AURA | 05153U107 | $4.0M | 1.13% | 595,744 | SH |
| 15 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $3.9M | 1.12% | 1,139,363 | SH |
| 16 | CARDIF ONCOLOGY INC | CRDF | 14147L108 | $2.9M | 0.81% | 1,762,084 | SH |
| 17 | Q32 BIO INC. | QTTB | 746964105 | $2.0M | 0.57% | 315,052 | SH |
| 18 | KARYOPHARM THERAPEUTICS INC | KPTI | 48576U205 | $1.6M | 0.46% | 287,826 | SH |
| 19 | JASPER THERAPEUTICS | JSPR | 471871202 | $1.2M | 0.35% | 1,411,492 | SH |
| 20 | X4 PHARMACEUTICALS INC | XFOR | 98420X103 | $966.6K | 0.27% | 234,039 | SH |
| 21 | BIOATLA INC | BCAB | 09077B104 | $865.0K | 0.25% | 5,406,345 | SH |
| 22 | VYNE THERAPEUTICS INC | VYNE | 92941V308 | $855 | 0.00% | 1,425 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | $351.8M | 22 | 0001636587-26-000029 |
| 2025-12-31 | 2026-02-17 | $295.1M | 21 | 0001636587-26-000005 |
| 2025-09-30 | 2025-11-17 | $197.0M | 20 | 0001636587-25-000060 |